Northwest Biotherapeutics, Inc. (NWBO)
USD 0.21
(-1.87%)
USD 0.21
(-1.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -55.5 Million USD | 17.38% |
| 2022 | -67.18 Million USD | -27.47% |
| 2021 | -52.7 Million USD | 39.15% |
| 2020 | -86.6 Million USD | -215.35% |
| 2019 | -27.46 Million USD | 33.79% |
| 2018 | -41.48 Million USD | 24.14% |
| 2017 | -54.67 Million USD | 31.02% |
| 2016 | -79.26 Million USD | 37.23% |
| 2015 | -126.28 Million USD | -24.86% |
| 2014 | -101.14 Million USD | -75.98% |
| 2013 | -57.47 Million USD | -31.14% |
| 2012 | -43.82 Million USD | -63.61% |
| 2011 | -26.78 Million USD | -74.46% |
| 2010 | -15.35 Million USD | 2.66% |
| 2009 | -15.77 Million USD | 27.05% |
| 2008 | -21.62 Million USD | -35.49% |
| 2007 | -15.95 Million USD | -166.1% |
| 2006 | -5.99 Million USD | 6.66% |
| 2005 | -6.42 Million USD | -0.74% |
| 2004 | -6.37 Million USD | 2.15% |
| 2003 | -6.51 Million USD | 58.65% |
| 2002 | -15.76 Million USD | -56.52% |
| 2001 | -10.07 Million USD | -46.17% |
| 2000 | -6.88 Million USD | -26.41% |
| 1999 | -5.45 Million USD | -21.65% |
| 1998 | -4.48 Million USD | -78.49% |
| 1997 | -2.51 Million USD | -104.07% |
| 1996 | -1.23 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -15.74 Million USD | -3.98% |
| 2024 Q2 | -17.46 Million USD | -10.92% |
| 2023 Q2 | -13.57 Million USD | -4.73% |
| 2023 FY | -55.5 Million USD | 17.38% |
| 2023 Q1 | -12.96 Million USD | 28.68% |
| 2023 Q4 | -15.14 Million USD | -9.53% |
| 2023 Q3 | -13.82 Million USD | -1.83% |
| 2022 Q4 | -18.17 Million USD | -16.39% |
| 2022 Q1 | -12.28 Million USD | -15.08% |
| 2022 FY | -67.18 Million USD | -27.47% |
| 2022 Q3 | -15.61 Million USD | 25.98% |
| 2022 Q2 | -21.09 Million USD | -71.73% |
| 2021 Q3 | -10.04 Million USD | 19.01% |
| 2021 Q4 | -10.67 Million USD | -6.24% |
| 2021 Q1 | -19.57 Million USD | 16.22% |
| 2021 Q2 | -12.4 Million USD | 36.6% |
| 2021 FY | -52.7 Million USD | 39.15% |
| 2020 FY | -86.6 Million USD | -215.35% |
| 2020 Q3 | -47.87 Million USD | -543.85% |
| 2020 Q2 | -7.43 Million USD | 3.84% |
| 2020 Q1 | -7.73 Million USD | -17.1% |
| 2020 Q4 | -23.35 Million USD | 51.21% |
| 2019 Q2 | -6.63 Million USD | 14.54% |
| 2019 FY | -27.46 Million USD | 33.79% |
| 2019 Q4 | -6.6 Million USD | -2.29% |
| 2019 Q3 | -6.45 Million USD | 2.73% |
| 2019 Q1 | -7.76 Million USD | -159.56% |
| 2018 FY | -41.48 Million USD | 24.14% |
| 2018 Q1 | -8.81 Million USD | 50.96% |
| 2018 Q2 | -20.35 Million USD | -130.88% |
| 2018 Q3 | -9.31 Million USD | 54.22% |
| 2018 Q4 | -2.99 Million USD | 67.89% |
| 2017 Q3 | -14.13 Million USD | -32.52% |
| 2017 FY | -54.67 Million USD | 31.02% |
| 2017 Q4 | -17.97 Million USD | -27.19% |
| 2017 Q2 | -10.66 Million USD | 10.41% |
| 2017 Q1 | -11.9 Million USD | 43.98% |
| 2016 Q3 | -25.51 Million USD | -69.85% |
| 2016 Q1 | -17.47 Million USD | 65.98% |
| 2016 Q4 | -21.24 Million USD | 16.73% |
| 2016 Q2 | -15.02 Million USD | 14.05% |
| 2016 FY | -79.26 Million USD | 37.23% |
| 2015 Q1 | -22.83 Million USD | 10.2% |
| 2015 FY | -126.28 Million USD | -24.86% |
| 2015 Q3 | -13.21 Million USD | 65.99% |
| 2015 Q4 | -51.38 Million USD | -288.9% |
| 2015 Q2 | -38.85 Million USD | -70.18% |
| 2014 Q2 | -25.42 Million USD | -7.37% |
| 2014 Q3 | -26.6 Million USD | -4.64% |
| 2014 Q4 | -25.42 Million USD | 4.45% |
| 2014 Q1 | -23.68 Million USD | -42.04% |
| 2014 FY | -101.14 Million USD | -75.98% |
| 2013 Q3 | -15.45 Million USD | -35.5% |
| 2013 Q1 | -13.94 Million USD | 10.5% |
| 2013 FY | -57.47 Million USD | -31.14% |
| 2013 Q4 | -16.67 Million USD | -7.9% |
| 2013 Q2 | -11.4 Million USD | 18.22% |
| 2012 Q3 | -13.74 Million USD | -57.29% |
| 2012 Q1 | -5.76 Million USD | -24.19% |
| 2012 FY | -43.82 Million USD | -63.61% |
| 2012 Q4 | -15.58 Million USD | -13.38% |
| 2012 Q2 | -8.73 Million USD | -51.55% |
| 2011 Q2 | -9.02 Million USD | -33.63% |
| 2011 FY | -26.78 Million USD | -74.46% |
| 2011 Q4 | -4.64 Million USD | 27.02% |
| 2011 Q3 | -6.36 Million USD | 29.54% |
| 2011 Q1 | -6.75 Million USD | -14.68% |
| 2010 Q1 | -3.34 Million USD | 3.88% |
| 2010 Q2 | -3.1 Million USD | 7.2% |
| 2010 Q3 | -3.01 Million USD | 3.09% |
| 2010 FY | -15.35 Million USD | 2.66% |
| 2010 Q4 | -5.89 Million USD | -95.71% |
| 2009 Q2 | -3.65 Million USD | 4.44% |
| 2009 Q3 | -4.81 Million USD | -31.63% |
| 2009 Q4 | -3.48 Million USD | 27.62% |
| 2009 FY | -15.77 Million USD | 27.05% |
| 2009 Q1 | -3.82 Million USD | 17.67% |
| 2008 Q3 | -5.29 Million USD | 11.8% |
| 2008 Q2 | -5.99 Million USD | -5.47% |
| 2008 Q1 | -5.68 Million USD | 18.35% |
| 2008 Q4 | -4.64 Million USD | 12.17% |
| 2008 FY | -21.62 Million USD | -35.49% |
| 2007 Q1 | -1.82 Million USD | -4.47% |
| 2007 Q3 | -3.56 Million USD | 1.3% |
| 2007 FY | -15.95 Million USD | -166.1% |
| 2007 Q2 | -3.6 Million USD | -98.08% |
| 2007 Q4 | -6.96 Million USD | -95.54% |
| 2006 Q4 | -1.74 Million USD | -22.56% |
| 2006 Q1 | -864 Thousand USD | 18.57% |
| 2006 Q3 | -1.42 Million USD | 27.62% |
| 2006 FY | -5.99 Million USD | 6.66% |
| 2006 Q2 | -1.96 Million USD | -127.55% |
| 2005 FY | -6.42 Million USD | -0.74% |
| 2005 Q4 | -1.06 Million USD | 43.77% |
| 2005 Q3 | -1.88 Million USD | -7.52% |
| 2005 Q2 | -1.75 Million USD | -2.15% |
| 2005 Q1 | -1.71 Million USD | 31.42% |
| 2004 FY | -6.37 Million USD | 2.15% |
| 2004 Q4 | -2.5 Million USD | -5.47% |
| 2004 Q3 | -2.37 Million USD | -206.45% |
| 2004 Q2 | -775 Thousand USD | -7.49% |
| 2004 Q1 | -721 Thousand USD | 12.71% |
| 2003 Q1 | -1.59 Million USD | 65.22% |
| 2003 FY | -6.51 Million USD | 58.65% |
| 2003 Q4 | -826 Thousand USD | 30.12% |
| 2003 Q3 | -1.18 Million USD | 59.49% |
| 2003 Q2 | -2.91 Million USD | -83.29% |
| 2002 Q3 | -3.52 Million USD | 21.44% |
| 2002 Q1 | -3.18 Million USD | 68.63% |
| 2002 FY | -15.76 Million USD | -56.52% |
| 2002 Q4 | -4.57 Million USD | -29.95% |
| 2002 Q2 | -4.48 Million USD | -40.89% |
| 2001 Q4 | -10.14 Million USD | -41219.64% |
| 2001 FY | -10.07 Million USD | -46.17% |
| 2001 Q3 | 24.67 Thousand USD | 0.0% |
| 2001 Q1 | 24.67 Thousand USD | 101.07% |
| 2001 Q2 | 24.67 Thousand USD | 0.0% |
| 2000 Q4 | -2.31 Million USD | -31.25% |
| 2000 FY | -6.88 Million USD | -26.41% |
| 2000 Q3 | -1.76 Million USD | 0.0% |
| 1999 FY | -5.45 Million USD | -21.65% |
| 1998 FY | -4.48 Million USD | -78.49% |
| 1997 FY | -2.51 Million USD | -104.07% |
| 1996 FY | -1.23 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -4056.561% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -1000.37% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -211.021% |
| Nascent Biotech, Inc. | -2.22 Million USD | -2389.283% |
| Rebus Holdings, Inc. | -664 Thousand USD | -8259.639% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 167.815% |
| Qrons Inc. | -643.67 Thousand USD | -8523.58% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -14148.53% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -13260.001% |
| Skye Bioscience, Inc. | -13.67 Million USD | -306.004% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 22.676% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 1229.403% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -21108.439% |
| SQZ Biotechnologies Company | -75.82 Million USD | 26.795% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -1847.303% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -3513.687% |
| Mesoblast Limited | -84.14 Million USD | 34.034% |
| Marizyme, Inc. | -34.08 Million USD | -62.844% |
| Genus plc | 6.4 Million USD | 967.313% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 669.753% |
| Pharming Group N.V. | -4.87 Million USD | -1037.565% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -2694.291% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -5859.759% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -564.766% |
| ContraFect Corporation | -56.88 Million USD | 2.428% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -1118.69% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -3859.227% |
| IMV Inc. | -38.67 Million USD | -43.537% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -1917.857% |
| MultiCell Technologies, Inc. | -722.81 USD | -7679373.167% |
| ONE Bio Corp. | 13.68 Million USD | 505.714% |
| Accustem Sciences Inc. | -3.74 Million USD | -1381.628% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 5.903% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -11390.865% |
| Q BioMed Inc. | -3.44 Million USD | -1510.975% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 1668.023% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -2012.561% |
| Biomind Labs Inc. | -1 Million USD | -5398.003% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -0.974% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -1813.244% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -734.956% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -2877.306% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -185223.184% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -249.773% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -2772.178% |
| GB Sciences, Inc. | -1.42 Million USD | -3807.613% |
| Alpha Cognition Inc. | -9.7 Million USD | -471.917% |
| HST Global, Inc. | -140.9 Thousand USD | -39293.359% |
| CSL Limited | 3.7 Billion USD | 101.499% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -4834.457% |
| Halberd Corporation | -75.05 Thousand USD | -73861.359% |
| Enzolytics Inc. | -2.14 Million USD | -2483.209% |
| Agentix Corp. | -1.37 Million USD | -3946.492% |
| Resverlogix Corp. | -12.74 Million USD | -335.391% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -1651.995% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 86.941% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -5216.858% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -1801.321% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -3414.599% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -1530.201% |
| AVAX Technologies, Inc. | 6.69 Million USD | 929.359% |
| Zenith Capital Corp. | -8.94 Million USD | -520.687% |
| Genscript Biotech Corporation | -415.79 Million USD | 86.65% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -318526.944% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -2160.726% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -32264.38% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -2668.814% |
| Kadimastem Ltd | -3.04 Million USD | -1725.771% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -5540.753% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -4319.427% |
| BioStem Technologies, Inc. | -7.77 Million USD | -613.565% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -30485.448% |
| LadRx Corporation | -3.82 Million USD | -1351.711% |
| Cell Source, Inc. | -4.32 Million USD | -1183.319% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -7980.355% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -7980.355% |
| NovAccess Global Inc. | -2.46 Million USD | -2150.239% |
| Affymax, Inc. | -15.04 Million USD | -268.922% |
| Itoco Inc. | -919.14 Thousand USD | -5939.124% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -1209.641% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -4860.5% |
| Mobile Lads Corp. | -554.55 Thousand USD | -9909.557% |
| CytoDyn Inc. | -18.05 Million USD | -207.387% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -220432.38% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -25121.967% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -9729.244% |
| SYBLEU INC | -149.18 Thousand USD | -37108.741% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -2956.069% |
| International Stem Cell Corporation | -663 Thousand USD | -8272.247% |
| Bioxytran, Inc. | -3.82 Million USD | -1353.033% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -105348.328% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -272800.688% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -53.058% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -3330.655% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -7443.539% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -1684.249% |
| Neutra Corp. | -229.48 Thousand USD | -24087.968% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -216.483% |
| PureTech Health plc | -146.19 Million USD | 62.033% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -158.283% |
| IXICO plc | -1.43 Million USD | -3762.77% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -484.849% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 54.429% |
| CSL Limited | 3.81 Billion USD | 101.456% |
| Cellectis S.A. | -108.85 Million USD | 49.008% |